Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. reports developments for a medical device business focused on procedural solutions for compromised bone and sacropelvic disorders. The company develops technologies centered on spinopelvic anatomy, including applications in minimally invasive SI joint fusion, adult spinal deformity, spinopelvic and sacropelvic fixation, and pelvic trauma.
Recurring updates include quarterly and annual financial results, revenue guidance, cash flow and adjusted EBITDA commentary, physician adoption metrics, reimbursement developments, and healthcare conference presentations. Product references include the iFuse Implant System, iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, iFuse 3D, and related surgical implant technologies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, a leader in musculoskeletal disorder solutions, will participate in the 2023 Bank of America Merrill Lynch Global Healthcare Conference. The event features a management fireside chat on May 9, 2023, at 1:55 p.m. Eastern Time. A live webcast will be accessible via the company's website with a 90-day post-event archive available for replay.
SI-BONE, known for the iFuse Implant System, has pioneered minimally invasive surgical treatments for SI joint disorders since 2009. With nearly 80,000 procedures performed by over 3,000 surgeons, SI-BONE enjoys wide insurance coverage for these treatments. This position enables continued advancements in clinical research and the commercialization of new surgical solutions for pelvic disorders.
SI-BONE, Inc. (Nasdaq: SIBN), a leader in surgical solutions for musculoskeletal disorders, will report its Q1 2023 financial results on May 1, 2023, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. Interested investors can register for the call through the provided link. The company has established a strong market position with over 80,000 SI joint fusion procedures performed using its iFuse Implant System, backed by extensive research and insurance coverage. SI-BONE continues to innovate in clinical applications and expand its offerings for sacropelvic conditions.
SI-BONE, Inc. (Nasdaq:SIBN) reported a strong financial performance for Q4 and full year 2022, with worldwide revenue reaching $32.0 million in Q4 and $106.4 million for the full year, reflecting increases of 27% and 18%, respectively. U.S. revenue was $30.0 million in Q4 and $98.8 million for 2022, driven mainly by increased domestic case volumes. Despite a net loss of $11.2 million in Q4 and $61.3 million for the full year, the company's adjusted EBITDA loss improved by 54%. Looking ahead, SI-BONE expects 2023 revenue to be between $124 million and $127 million, with a projected gross margin of 80%.
SI-BONE, Inc. (Nasdaq: SIBN), a leader in musculoskeletal disorder solutions, will announce its fourth quarter 2022 financial results on February 27, 2023, after market close. The company also plans a conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via registration. Since launching the iFuse Implant System in 2009, over 75,000 SI joint fusion procedures have been performed by more than 3,000 surgeons. SI-BONE has achieved extensive coverage from various insurance payors for minimally invasive SI joint fusion procedures, enhancing its market position and supporting ongoing clinical research and new treatment developments.